Programmed longevity, youthspan, and juventology – lifespans and Healthspan

Volter Longo has some interesting new ideas regarding how we look at life expectancy, lifespan. He recommends thinking about spans in terms of youthspan (peak health 20-60) and Healthspan (oriented to disease free stage and the older phase (65-120).

check – Longo VD. Programmed longevity, youthspan, and juventology. Aging Cell. 2019;18:e12843. https://doi.org/10.1111/acel.12843 

also check David Sinclair’s new book Lifespan: Why We Age―and Why We Don’t Have To — is a really great book! Highly recommended …. packed with information … some should be taken with a grain of salt or maybe with a Sirtuin activator like NMN 🙂

 

 

Advertisements

Mediterranean diet and telomere length

Looking at

 

Conclusion In this large study, greater adherence to the Mediterranean diet was associated with longer telomeres. These results further support the benefits of adherence to the Mediterranean diet for promoting health and longevity.”

So,  that seems promising … the question….. can you ‘stick with the diet’?  Of course, there are other studies that provide other results.  How does one resolve the discrepancies?

Stat tuned … Ideas coming soon 🙂

 

in the meanwhile some people like these dish ideas

 

Watson for Oncology (WFO) – more details

Back to Watson for Oncology (WFO). … so today was deep dive day to look at what papers were written specifically re WFO.

So,  on Sunday, June 23, 2019, using Google Scholar … the list below is of  the main useful things I could find.

Conclusions:

  • Shows promise
  • Not ready for solo flight (i.e. needs clinicians to work with it).
  • Benefits from adding diagnostic tests liken GEA (Gene expression assays)
  • Keep working on improving WFO, and understand specifics better.

 

Literature I looked at, will look at it again in more detail, and provide further insights.

  1. Choi, Y. I., Chung, J. W., Kim, K. O., Kwon, K. A., Kim, Y. J., Park, D. K., … & Sung, K. H. (2019). Concordance Rate between Clinicians and Watson for Oncology among Patients with Advanced Gastric Cancer: Early, Real-World Experience in Korea. Canadian Journal of Gastroenterology and Hepatology, 2019.
  2. Kim, Y. Y., Oh, S. J., Chun, Y. S., Lee, W. K., & Park, H. K. (2018). Gene expression assay and Watson for Oncology for optimization of treatment in ER-positive, HER2-negative breast cancer. PloS one, 13(7), e0200100.
  3. Schmidt, C. (2017). MD Anderson breaks with IBM Watson, raising questions about artificial intelligence in oncology. JNCI: Journal of the National Cancer Institute, 109(5).
  4. Zhang, X. C., Zhou, N., Zhang, C. T., Lv, H. Y., Li, T. J., Zhu, J. J., … & Liu, G. (2017). 544P Concordance study between IBM Watson for Oncology (WFO) and clinical practice for breast and lung cancer patients in China. Annals of Oncology, 28(suppl_10), mdx678-001.
  5. Zou, F., Liu, C. Y., Liu, X. H., Tang, Y. F., Ma, J. A., & Hu, C. H. (2018). Concordance Study between IBM Watson for Oncology and Real Clinical Practice for Cervical Cancer Patients in China: A Retrospective Analysis. Available at SSRN 3287513.
  6. Somashekhar, S. P., Sepúlveda, M. J., Puglielli, S., Norden, A. D., Shortliffe, E. H., Rohit Kumar, C., … & Ramya, Y. (2018). Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board. Annals of Oncology, 29(2), 418-423.
  7. Somashekhar, S. P., Sepúlveda, M. J., Norden, A. D., Rauthan, A., Arun, K., Patil, P., … & Kumar, R. C. (2017). Early experience with IBM Watson for Oncology (WFO) cognitive computing system for lung and colorectal cancer treatment.
  8. Somashekhar, S. P., Kumarc, R., Rauthan, A., Arun, K. R., Patil, P., & Ramya, Y. E. (2017). Abstract S6-07: Double blinded validation study to assess performance of IBM artificial intelligence platform, Watson for oncology in comparison with Manipal multidisciplinary tumour board–First study of 638 breast cancer cases.
  9. Liu, C., Liu, X., Wu, F., Xie, M., Feng, Y., & Hu, C. (2018). Using artificial intelligence (Watson for oncology) for treatment recommendations amongst Chinese patients with lung cancer: Feasibility study. Journal of medical Internet research, 20(9), e11087.
  10. Ross, C., & Swetlitz, I. (2017). IBM pitched its Watson supercomputer as a revolution in cancer care. It’s nowhere close. STAT News.
  11. Zauderer, M. G., Gucalp, A., Epstein, A. S., Seidman, A. D., Caroline, A., Granovsky, S., … & Petri, J. (2014). Piloting IBM Watson Oncology within Memorial Sloan Kettering’s regional network.
  12. Herath, D. H., Wilson-Ing, D., Ramos, E., & Morstyn, G. (2016). Assessing the natural language processing capabilities of IBM Watson for oncology using real Australian lung cancer cases.
  13. Bach, P., Zauderer, M. G., Gucalp, A., Epstein, A. S., Norton, L., Seidman, A. D., … & Keesing, J. (2013). Beyond Jeopardy!: Harnessing IBM’s Watson to improve oncology decision making.
  14. Kris, M. G., Gucalp, A., Epstein, A. S., Seidman, A. D., Fu, J., Keesing, J., … & Setnes, M. (2015). Assessing the performance of Watson for oncology, a decision support system, using actual contemporary clinical cases.